Valuation: Theracryf Plc

Market Cap 64.95L 58.04L 54.15L 49.18L 92.63L 63Cr 93.32L 6.51Cr 2.54Cr 32Cr 2.44Cr 2.39Cr 102.73Cr P/E 2026
-1.21x
P/E 2027 * -2x
Enterprise Value 43.36L 38.74L 36.14L 32.83L 61.83L 42Cr 62.29L 4.34Cr 1.7Cr 21Cr 1.63Cr 1.59Cr 69Cr EV / Sales 2026
-
EV / Sales 2027 * -
Free-Float
64.1%
Yield 2026 *
-
Yield 2027 * -
1 day+1.89%
1 week+1.89%
Current month+1.89%
1 month-0.86%
3 months-14.70%
6 months-5.95%
Current year-8.30%
1 week 0.17
Extreme 0.17
0.19
1 month 0.16
Extreme 0.16
0.2
Current year 0.16
Extreme 0.16
0.27
1 year 0.16
Extreme 0.16
0.27
3 years 0.16
Extreme 0.16
2.1
5 years 0.16
Extreme 0.16
7.8
10 years 0.16
Extreme 0.16
30.25
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/25
Tracarta Ltd.
BuyCompany 73,42,296 0.3448%
22/05/25 Others

Director

42,27,27,272 19.8499%
04/03/25 Buy

Chief Operating Officer

15,00,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
+1.89%+1.89%-14.70%-90.09% 64.95L
+4.16%+4.16%+49.37%+94.17% 7.47TCr
-18.22%-18.49%-0.17%+46.90% 5.87TCr
-1.56%+1.43%+4.37%+32.54% 4.84TCr
+0.50%-2.14%+331.33%+702.20% 4.31TCr
-0.72%-3.99%+28.50%+29.94% 4.25TCr
+0.34%-0.52%+6.56%+109.35% 4.14TCr
-0.11%+1.96%+9.19%+52.66% 3.13TCr
-0.50%-3.10%-10.19%-14.35% 2.39TCr
-3.32%-10.86%-37.32%+316.28% 2.22TCr
Average -1.75%-1.96%+36.69%+127.96% 3.86TCr
Weighted average by Cap. -2.37%-1.56%+48.82%+144.31%

Financials

2026 2027 *
Net sales - -
Net income -33.79L -30.19L -28.17L -25.59L -48.19L -33Cr -48.55L -3.39Cr -1.32Cr -17Cr -1.27Cr -1.24Cr -53Cr -29.55L -26.41L -24.64L -22.38L -42.14L -29Cr -42.46L -2.96Cr -1.16Cr -15Cr -1.11Cr -1.09Cr -47Cr
Net Debt -21.6L -19.3L -18L -16.35L -30.8L -21Cr -31.03L -2.16Cr -84.52L -11Cr -81.08L -79.33L -34Cr -68.93T -61.59T -57.46T -52.19T -98.3T -66.68L -99.03T -7L -3L -33.91L -3L -3L -1.09Cr
Projected Income Statement - Annual - Theracryf Plc
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
08/26/08 GBX 0.1834 +1.89% 1,33,615
07/26/07 GBX 0.1800 0.00% 10,034
06/26/06 GBX 0.1800 0.00% 3,41,969
05/26/05 GBX 0.1800 0.00% 1,56,365
02/26/02 GBX 0.1800 0.00% 10,57,427
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002377USD
Average target price
0.0159USD
Spread / Average Target
+568.42%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Theracryf Plc